Johnson & Johnson's investigational drug nipocalimab significantly reduced disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) during a Phase 2 study, with effects sustained through 52 weeks. The drug targets pathogenic IgG autoantibodies, addressing the underlying cause of SLE while preserving immune function. Results showed greater benefits in patients positive for lupus-associated autoantibodies, representing about 80% of SLE cases. A Phase 3 trial is currently underway, and nipocalimab has received Fast Track designation from the FDA for SLE treatment.
Johnson & Johnson's nipocalimab, a novel FcRn blocker, met its primary endpoint by significantly reducing disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) at 24 weeks, with benefits sustained through 52 weeks in a...
Johnson & Johnson announced new Phase 2 data for nipocalimab, an immunoselective FcRn blocker, showing greater clinical response in Sjögren's disease patients with elevated autoantibodies and IgG levels. The drug reduced disease activity and symptoms...
Nanobiotix completed a €86.1 million follow-on offering in May 2026 to accelerate development of its nanotherapeutic platforms. New data from its Phase 2 study of JNJ-1900 (NBTXR3) in Stage 3 inoperable non-small cell lung cancer showed promising res...
Legend Biotech, a leader in cell therapy, reported that its CAR-T treatment CARVYKTI generated nearly $2 billion in sales in 2025. CARVYKTI, developed and co-promoted with Johnson & Johnson, is a one-time infusion therapy for multiple myeloma and has...
Johnson & Johnson's Phase 3 PROTEUS study shows ERLEADA (apalutamide) combined with hormone therapy before and after surgery significantly improves outcomes for high-risk localized prostate cancer patients. The treatment increased the chance of minim...
